Tick-borne Encephalitis and Positive Borrelial Antibodies

Tick-borne Encephalitis Clinical Trial

— TBE-LB2014  

Official title:

Management of Patients With Tick-borne Encephalitis and Positive Anti-Lyme Borreliae Antibody Results

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02463942
• Other study ID #: TBE-LB2014
• Status: Recruiting
• Phase: N/A
• Start date: September 2014
• Est. completion date: September 2020

Study information

• Verified date: May 2018
• Source: University Medical Centre Ljubljana
• Contact: Daša Stupica, MD, PhD
• Phone: +386 1 5222110
• Email: dasa.stupica[@]kclj.si
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Slovenia, tick-borne encephalitis and Lyme borreliosis are both endemic diseases with high incidence rates and they are both transmitted by a bite of infected Ixodes ricinus tick. In clinical practice, tick-borne encephalitis is confirmed by demonstration of tick-borne encephalitis antibodies in serum of a patient with compatible clinical presentation and cerebrospinal pleocytosis. Patients with Lyme meningitis or meningoradiculitis also have cerebrospinal pleocytosis, however the presence of borrelial antibodies in serum does not attest Lyme neuroborreliosis.

Patients with tick-borne encephalitis and positive borrelial antibodies in serum, but not fulfilling criteria for Lyme neuroborreliosis, are often being treated with antibiotics in several European countries due to the possibility of double infection. The investigators hypothesise that such patients do not benefit from antibiotics. Such an approach may appear safe regarding the possibility of borrelial infection, however it can also be associated with detrimental consequences such as antibiotic related adverse reactions, negative epidemiological impact on bacterial resistance, and intravenous catheter related complications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 2020
• Est. primary completion date: September 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older

• clinical picture compatible with tick-borne encephalitis,

• clear cerebrospinal fluid,

• cerebrospinal pleocytosis (leucocytes in cerebrospinal fluid >5 x 106/)L,

• positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against tick-borne encephalitis virus,

• positive serum IgG antibodies against Lyme borreliae.

Exclusion Criteria:

• isolation of B.burgdorferi sensu lato from cerebrospinal fluid,

• positive intrathecal borrelial antibody production index,

• seroconversion of borrelial IgG antibodies,

• presence of erythema migrans and/or borrelial lymphocytoma in the last month,

• Bannwarth syndrome.

Related Conditions & MeSH terms

• Encephalitis
• Encephalitis, Tick-Borne
• Tick-borne Encephalitis

Intervention

Drug:
• Doxycycline
Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
• Symptomatic therapy
Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.

Other:
• Questionnaire
Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.

Locations

Country	Name	City	State
Slovenia	UMC Ljubljana, Department of Infectious Diseases	Ljubljana

Sponsors (2)

Lead Sponsor	Collaborator
University Medical Centre Ljubljana	University of Ljubljana School of Medicine, Slovenia

Country where clinical trial is conducted

Slovenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective manifestations of Lyme borreliosis		one year
Primary	Frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia		one year